As HIF-2α, VEGFR1 and VEGFR2 are the main drug targets of anti-angiogenic therapies in m-ccRCC, high expression of miRNAs that target them would lead to decreased translation of HIF-2α, VEGFR1 or VEGFR2, possibly resulting in decreased therapeutic efficiency of HIF-2α inhibitors or VEGFR-TKIs. This evidence concerns the gene KDR and nonpapillary renal cell carcinoma.